MedTrace Logo

Tenofovir Pharmacology in Older HIV Infected Individuals

NCT02304263 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2016-09-26

No results posted yet for this study

Summary

Tenofovir continues to play a vital role in the treatment of the human immunodeficiency virus (HIV) and as the age of the HIV-infected population increases in the United States and worldwide, there is an urgent need to understand the extent to which older age influences the way this antiretroviral medication works in the body. The investigators study aims to characterize and compare the pharmacology of tenofovir in older versus younger HIV-infected adults and to assess kidney function over the course of approximately one year. The investigators will be analyzing tenofovir levels in different compartments of the blood and in hair samples, and will be assessing the relationship between tenofovir concentrations and changes in kidney function over time in the older and younger cohorts. Lastly, the investigators will be evaluating the relationship between tenofovir concentrations and functional status (including body composition, bone mineral density, and frailty) in study participants.

Conditions

Interventions

DRUG

iohexol

5mL bolus of 300 mg/ml iohexol (Omnipaque) over 2 minutes

Sponsors & Collaborators

Principal Investigators

  • Sharon M Seifert, PharmD · University of Colorado, Denver

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2016-09-30
Completion
2016-09-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02304263 on ClinicalTrials.gov